Google
GPCR Stock Price & Analysis — Structure Therapeutics Inc. American Depositary Shares (Healthcare >> Biotechnology)
GPCR FAQ
What is GPCR's P/E ratio?
Structure Therapeutics Inc. American Depositary Shares (GPCR) currently trades at a P/E ratio of 103.45.
What is GPCR's ROE?
Structure Therapeutics Inc. American Depositary Shares reports a Return on Equity (ROE) of -11.79%.
What is GPCR's dividend yield?
Structure Therapeutics Inc. American Depositary Shares offers a dividend yield of 0.00%.
What is GPCR's Quality Score?
Our AI rates GPCR's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GPCR?
Our AI Timing Score for GPCR is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GPCR belong to?
Structure Therapeutics Inc. American Depositary Shares is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
GPCR AI Analysis Summary
Our AI summary for GPCR: Structure Therapeutics Inc. American Depositary Shares (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 103.45, ROE of -11.79%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 48.36
Price
0.32
(0.67%)
Day Change
|
|
|---|
GPCR, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 48.36 |
| PBV / Sector |
2.36 / 44,219.29
|
| Earning Per Share | -2.42 |
| PE / Sector |
103.45 / 19.28
|
| PEG or PE/Growth / Sector |
4.32 / 1.23
|
| Average 1M Daily Value |
26.75 M
GREAT
|
| Average 1W Daily Value |
19.13 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-04 08:01:36 |
| Symbol | GPCR |
| Name | STRUCTURE THERAPEUTICS INC. AMERICAN DEPOSITARY SHARES |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 71.07 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,414.42 / 9,645.64 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 601 Gateway Boulevard, South San Francisco, CA, United States, 94080
Phone: 650 457 1978
Website: https://structuretx.com
Employees: 233
Sector: Healthcare >> Biotechnology
Description: Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap